未登录

J

Jelena Pavlović

Albert Einstein College of Medicine

H指数:28

被引数:2,848

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recruitment of mid-life adults to a randomized clinical trial: The multicultural healthy diet study to reduce cognitive decline and Alzheimer's disease risk

招募中年成年人参与随机临床试验：降低认知衰退和阿尔茨海默病风险的多元文化健康饮食研究

Alzheimer's & Dementia: Translational Research & Clinical Interventions

IF0

2025-11-140

OAAI

Efficacy and safety of rimegepant 75 mg for acute treatment of migraine: a pooled analysis of four randomized, placebo-controlled trials

瑞美吉泮75 mg治疗急性偏头痛的疗效与安全性：一项四项随机、安慰剂对照试验的合并分析

Postgraduate Medicine

IF2.8

2025-06-130

PRE

The effects of the Multicultural Healthy Diet on cognitive decline and Alzheimer’s disease risk: a phase II randomized controlled trial in middle-aged adults

多元文化健康饮食对认知衰退和阿尔茨海默病风险的影响：一项针对中年人群的II期随机对照试验

The American Journal of Clinical Nutrition

IF0

2025-05-220

PRE

The Relation Between Systemic Inflammation and the Menopause Transition: The Study of Women's Health Across the Nation

系统性炎症与绝经过渡期之间的关系：全国女性健康研究

The Journal of Clinical Endocrinology & Metabolism

IF5.1

2025-03-240

OA

Relation of Migraine to Stroke Risk in Postmenopausal Women: Findings from the Women's Health Initiative

绝经后女性偏头痛与卒中风险的关系：妇女健康倡议研究的结果

IF8.9

2025-02-010

PRE

Enlarged Breast Size (Macromastia) and Associated Neurologic Risks: A Scoping Review

IF8.5

2024-08-130

PRE

Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks

IF4

2024-07-033

OA

Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2

galcanezumab对符合月经相关性偏头痛标准的发作性偏头痛女性的影响: EVOLVE-1和EVOLVE-2的事后分析

IF4

2023-11-281

OAAI

Sleep Symptoms and Disorders in Episodic Migraine: Assessment and Management

CURRENT PAIN AND HEADACHE REPORTS

IF3.5

2023-09-044

PRE

Zavegepant 10 mg Nasal Spray is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials

IF8.5

2023-04-251

PRE

Broad Inclusion of Roles for a Neurology Department Diversity, Equity, and Inclusion Committee: Working Towards a Future of DEI Throughout Medicine

IF8.5

2023-04-250

PRE

Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine

IF8.5

2023-04-250

PRE

Long-Term Safety and Tolerability of Zavegepant 10 mg Nasal Spray During Concomitant Use of CGRP Monoclonal Antibodies: Results From a 1-Year Open-label Safety Trial

IF8.5

2023-04-251

PRE

Long-Term Preventive and Acute Treatment of Migraine With Rimegepant Improves Health Related Quality of Life

IF8.5

2023-04-250

PRE

Efficacy of Zavegepant Nasal Spray for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials

IF8.5

2023-04-251

PRE

Rimegepant for the Acute and Preventive Treatment of Migraine in Women: Results From 4 Randomized, Placebo-Controlled Clinical Trials

IF8.5

2023-04-250

PRE

Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial

IF8.5

2023-04-250

PRE

Patterns of Medication Utilization and Migraine Frequency in Adults Using Rimegepant for Both Preventive and Acute Treatment for Migraine: Results From a 52-Week, Open-Label Extension Study

IF8.5

2023-04-250

PRE

Zavegepant Nasal Spray for the Acute Treatment of Migraine With Aura and Without Aura: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials

IF8.5

2023-04-251

PRE

Interrelationships of Sleep Quality, Obesity Severity, and Clinical Headache Features among Women with Comorbid Migraine and Obesity

JOURNAL OF CLINICAL MEDICINE

IF2.9

2023-02-222

OAAI